Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1a50c0f9-fffe-4173-99f6-480a9a6c4c27&Preview=1
Date 5/11/2011
Company Name Naurex
Mailing Address 1801 Maple Ave. Evanston, IL 60201
Company Description Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR).
Proceeds Purposes Naurex will use the proceeds from the Series A financing primarily for the Phase II trial of its lead compound, GLYX-13, a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), and also to advance its second-generation GFPA program.